Kolon Life Science Inc
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for ant… Read more
Kolon Life Science Inc (102940) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.007x
Based on the latest financial reports, Kolon Life Science Inc (102940) has a cash flow conversion efficiency ratio of 0.007x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.58 Billion) by net assets (₩346.41 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kolon Life Science Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Kolon Life Science Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kolon Life Science Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kolon Life Science Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Xiantong Rubber&Plastic Co Ltd
SHG:603239
|
0.061x |
|
STEF S.A
LSE:0NY3
|
0.097x |
|
Cosmecca Korea Co. Ltd
KQ:241710
|
0.053x |
|
Otc Markets Group
OTCQX:OTCM
|
0.253x |
|
Infibeam Avenues Limited
NSE:INFIBEAM
|
0.023x |
|
IRPC PCL -NVDR- BA 1
F:NVPF
|
N/A |
|
Garware Hi-Tech Films Limited
NSE:GRWRHITECH
|
0.008x |
|
Frey SA
PA:FREY
|
0.059x |
Annual Cash Flow Conversion Efficiency for Kolon Life Science Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Kolon Life Science Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩149.34 Billion | ₩-14.08 Billion | -0.094x | +47.78% |
| 2023-12-31 | ₩137.67 Billion | ₩-24.87 Billion | -0.181x | -45.27% |
| 2022-12-31 | ₩167.72 Billion | ₩-20.85 Billion | -0.124x | +23.64% |
| 2021-12-31 | ₩99.41 Billion | ₩-16.19 Billion | -0.163x | -29.16% |
| 2020-12-31 | ₩57.96 Billion | ₩-7.31 Billion | -0.126x | +36.89% |
| 2019-12-31 | ₩101.02 Billion | ₩-20.18 Billion | -0.200x | -555.43% |
| 2018-12-31 | ₩446.15 Billion | ₩-13.60 Billion | -0.030x | -100.45% |
| 2017-12-31 | ₩545.41 Billion | ₩-8.29 Billion | -0.015x | -114.05% |
| 2016-12-31 | ₩259.79 Billion | ₩28.11 Billion | 0.108x | -29.56% |
| 2015-12-31 | ₩135.44 Billion | ₩20.81 Billion | 0.154x | +72.96% |
| 2014-12-31 | ₩136.17 Billion | ₩12.10 Billion | 0.089x | -- |